-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Alpha Teknova (NASDAQ:TKNO) Versus Achieve Life Sciences (NASDAQ:ACHV) Head-To-Head Contrast
Alpha Teknova (NASDAQ:TKNO) Versus Achieve Life Sciences (NASDAQ:ACHV) Head-To-Head Contrast
Alpha Teknova (NASDAQ:TKNO – Get Rating) and Achieve Life Sciences (NASDAQ:ACHV – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Profitability
This table compares Alpha Teknova and Achieve Life Sciences' net margins, return on equity and return on assets.
Get Alpha Teknova alerts:| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -86.67% | -16.09% | -12.24% |
| Achieve Life Sciences | N/A | -240.36% | -104.96% |
Valuation & Earnings
This table compares Alpha Teknova and Achieve Life Sciences' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $36.89 million | 4.64 | -$9.80 million | ($1.35) | -4.52 |
| Achieve Life Sciences | N/A | N/A | -$33.15 million | ($3.99) | -1.18 |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Alpha Teknova and Achieve Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 0 | 0 | 1 | 0 | 3.00 |
| Achieve Life Sciences | 0 | 0 | 2 | 0 | 3.00 |
Alpha Teknova currently has a consensus target price of $9.33, indicating a potential upside of 53.01%. Achieve Life Sciences has a consensus target price of $17.33, indicating a potential upside of 268.01%. Given Achieve Life Sciences' higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Alpha Teknova.
Institutional and Insider Ownership
22.7% of Alpha Teknova shares are owned by institutional investors. Comparatively, 21.1% of Achieve Life Sciences shares are owned by institutional investors. 15.2% of Alpha Teknova shares are owned by insiders. Comparatively, 1.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Alpha Teknova has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Summary
Alpha Teknova beats Achieve Life Sciences on 7 of the 12 factors compared between the two stocks.
About Alpha Teknova
(Get Rating)
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
About Achieve Life Sciences
(Get Rating)
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
Alpha Teknova (NASDAQ:TKNO – Get Rating) and Achieve Life Sciences (NASDAQ:ACHV – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
纳斯达克：TKNO-GET评级)和成就生命科学(纳斯达克：ACHV-GET评级)都是小盘医疗公司，但哪只股票更具优势？我们将根据两家公司的股息、收益、风险、估值、分析师建议、盈利能力和机构持股情况对它们进行比较。
Profitability
盈利能力
This table compares Alpha Teknova and Achieve Life Sciences' net margins, return on equity and return on assets.
此表比较了Alpha Tenowva和ACENTH Life Science的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -86.67% | -16.09% | -12.24% |
| Achieve Life Sciences | N/A | -240.36% | -104.96% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 阿尔法·特克诺瓦 | -86.67% | -16.09% | -12.24% |
| 实现生命科学 | 不适用 | -240.36% | -104.96% |
Valuation & Earnings
估值与收益
This table compares Alpha Teknova and Achieve Life Sciences' gross revenue, earnings per share (EPS) and valuation.
下表比较了阿尔法·泰克诺瓦和实现生命科学的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $36.89 million | 4.64 | -$9.80 million | ($1.35) | -4.52 |
| Achieve Life Sciences | N/A | N/A | -$33.15 million | ($3.99) | -1.18 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 阿尔法·特克诺瓦 | 3,689万美元 | 4.64 | -980万元 | ($1.35) | -4.52 |
| 实现生命科学 | 不适用 | 不适用 | -3,315万元 | ($3.99) | -1.18 |
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and price targets for Alpha Teknova and Achieve Life Sciences, as provided by MarketBeat.com.
这是由MarketBeat.com提供的阿尔法·特克诺瓦和实现生命科学公司最近的评级和目标价细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 0 | 0 | 1 | 0 | 3.00 |
| Achieve Life Sciences | 0 | 0 | 2 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 阿尔法·特克诺瓦 | 0 | 0 | 1 | 0 | 3.00 |
| 实现生命科学 | 0 | 0 | 2 | 0 | 3.00 |
Alpha Teknova currently has a consensus target price of $9.33, indicating a potential upside of 53.01%. Achieve Life Sciences has a consensus target price of $17.33, indicating a potential upside of 268.01%. Given Achieve Life Sciences' higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Alpha Teknova.
阿尔法·特克诺瓦目前的共识目标价为9.33美元，表明潜在上行空间为53.01%。实现生命科学公司的共识目标价为17.33美元，表明潜在上涨268.01%。考虑到成就生命科学公司更有可能的上行空间，分析师们显然认为，成就生命科学公司比阿尔法·特克诺瓦更有利。
Institutional and Insider Ownership
机构和内部人持股
22.7% of Alpha Teknova shares are owned by institutional investors. Comparatively, 21.1% of Achieve Life Sciences shares are owned by institutional investors. 15.2% of Alpha Teknova shares are owned by insiders. Comparatively, 1.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Alpha Tenowva 22.7%的股份由机构投资者持有。相比之下，实现生命科学公司21.1%的股份由机构投资者持有。阿尔法公司15.2%的股份由内部人士持有。相比之下，实现生命科学1.0%的股份由内部人士持有。强大的机构持股表明，捐赠基金、大型基金管理公司和对冲基金相信，一家公司有望实现长期增长。
Risk and Volatility
风险和波动性
Alpha Teknova has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Alpha Tenowva的贝塔系数为0.22，这意味着其股价的波动性比标准普尔500指数低78%。相比之下，实现生命科学的贝塔系数为1.22，这意味着其股价的波动性比标准普尔500指数高22%。
Summary
摘要
Alpha Teknova beats Achieve Life Sciences on 7 of the 12 factors compared between the two stocks.
阿尔法·特克诺瓦在两只股票比较的12个因素中有7个超过了实现生命科学。
About Alpha Teknova
关于阿尔法·特克诺瓦
(Get Rating)
(获取评级)
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
阿尔法·特诺瓦公司为美国和国际上的生命科学市场提供关键试剂。它的试剂使生物制药产品的发现、开发和生产成为可能，如药物疗法、新型疫苗和分子诊断。该公司提供用于细胞生长和克隆的预先浇注的培养基板；用于细胞扩增的液体细胞培养液和补充剂；以及用于样品处理、再悬浮和纯化的分子生物试剂。它服务于生命科学市场，包括制药和生物技术公司、合同开发和制造组织、体外诊断特许经营权以及学术和政府研究机构。该公司成立于1996年，总部设在加利福尼亚州霍利斯特。
About Achieve Life Sciences
关于实现生命科学
(Get Rating)
(获取评级)
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
成就生命科学公司是一家临床阶段的制药公司，致力于用于戒烟的西替尼克林的开发和商业化。其产品包括胞苷，一种以植物为基础的生物碱，与烟碱型乙酰胆碱受体具有结合亲和力。该公司成立于1991年10月，总部设在加拿大温哥华。
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
接收阿尔法·特克诺瓦日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Alpha Tenowva和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧